Västra Hamnen publishes initial analysis of CombiGene

CombiGene AB (publ) (“CombiGene”, the “Company”) announces today that Västra Hamnen Corporate Finance, in its initial analysis of the Company, values CombiGene at SEK 12.19 per share.

The analysis is the first one that Västra Hamnen has carried out of CombiGene since the collaboration began in April 2024. It is based on a risk-adjusted DCF model, which indicates a fair value. The analysis is published on Västra Hamnen's website and available here.

“Västra Hamnen's analysis highlights the potential that exists in our projects, which are aimed at large patient groups where effective and sustainable treatments are currently lacking. As our work progresses towards the set milestones, the risk in the projects decreases, which positively affects the valuation,” comments CombiGene's CEO Peter Ekolind.

Datum 2024-06-25, kl 15:00
Källa MFN
Hej Serverägare! Har du problem med troll och spam? Nu finns möjligheten att sätta en liten avgift, t.ex. 20kr, på discord invites och därmed stoppa många återkommande troll samtidigt som du tjänar lite pengar. Kolla in Invite Paywall.